New Bladder-Sparing combo aims to avoid surgery in cancer patients
NCT ID NCT07663747
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a combination of two drugs—enfortumab vedotin (Padcev) and pembrolizumab (Keytruda)—can help people with muscle-invasive bladder cancer avoid bladder removal. About 56 participants will receive the drugs first, and those who respond well may get radiation or just observation instead of surgery. The goal is to see if this approach keeps the cancer away while preserving the bladder for at least two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda)
What this could lead to
If successful, this approach could allow many patients with bladder cancer to keep their bladder instead of having it removed, while still controlling the disease.
What could go wrong
This is an early phase 2 trial with only 56 participants, so results may not apply broadly. The combination therapy can cause significant side effects, and some patients may still need surgery or radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Antoni van Leeuwenhoek ziekenhuis
Amsterdam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Leiden University Medical Center Leiden (LUMC)
Leiden, Netherlands
Contact Phone: •••-•••-••••
-
University Medical Center Utrecht(UMCU)
Utrecht, Netherlands
Contact Phone: •••-•••-••••